Birdwatch Note
2023-07-08 22:13:57 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp
Written by 138198C85323D434507B2D6B1EAA57F537E7C975E5407BEDD3105176AA6F0409
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1677542277462507520
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1677803233077522432
- noteId - 1677803233077522432
- participantId -
- noteAuthorParticipantId - 138198C85323D434507B2D6B1EAA57F537E7C975E5407BEDD3105176AA6F0409 Participant Details
- createdAtMillis - 1688854437500
- tweetId - 1677542277462507520
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-07-08 22:13:57 UTC (1688854437500) |
1969-12-31 23:59:59 UTC (-1) |
2023-07-09 17:10:50 UTC (1688922650332) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-07-08 19:20:16 -0500 | Rating Details | |
| 2023-07-08 19:11:53 -0500 | Rating Details | |
| 2023-07-08 18:51:23 -0500 | Rating Details | |
| 2023-07-08 17:29:21 -0500 | Rating Details | |
| 2023-07-08 17:20:20 -0500 | Rating Details | |
| 2023-07-09 12:17:34 -0500 | Rating Details | |
| 2023-07-09 12:13:42 -0500 | Rating Details | |
| 2023-07-09 11:40:14 -0500 | Rating Details | |
| 2023-07-09 11:03:15 -0500 | Rating Details | |
| 2023-07-09 10:31:21 -0500 | Rating Details | |
| 2023-07-09 07:46:11 -0500 | Rating Details | |
| 2023-07-09 07:33:44 -0500 | Rating Details | |
| 2023-07-09 07:24:16 -0500 | Rating Details | |
| 2023-07-09 07:22:45 -0500 | Rating Details | |
| 2023-07-09 03:36:35 -0500 | Rating Details | |
| 2023-07-09 03:29:17 -0500 | Rating Details | |
| 2023-07-09 02:48:20 -0500 | Rating Details | |
| 2023-07-09 02:18:03 -0500 | Rating Details | |
| 2023-07-09 00:42:20 -0500 | Rating Details | |
| 2023-07-09 00:33:46 -0500 | Rating Details | |
| 2023-07-09 00:08:24 -0500 | Rating Details | |
| 2023-07-08 21:26:18 -0500 | Rating Details | |
| 2023-07-08 21:17:15 -0500 | Rating Details | |
| 2023-07-08 20:47:48 -0500 | Rating Details | |
| 2023-07-08 20:42:30 -0500 | Rating Details | |
| 2023-07-08 19:57:18 -0500 | Rating Details | |
| 2023-07-08 19:46:44 -0500 | Rating Details | |
| 2023-07-08 19:35:08 -0500 | Rating Details | |
| 2023-07-10 11:21:05 -0500 | Rating Details | |
| 2023-07-10 08:50:37 -0500 | Rating Details | |
| 2023-07-11 12:27:51 -0500 | Rating Details | |
| 2023-07-10 19:48:06 -0500 | Rating Details | |
| 2023-07-10 19:42:24 -0500 | Rating Details |